FDA Starts Public Discussion on the Next Drug Fee Renewal
Published Date: 5/19/2025
Notice
Summary
The FDA is gearing up to renew the Prescription Drug User Fee Act (PDUFA) for 2028-2032, which lets them collect fees to speed up drug reviews. This affects drug makers and patients waiting for new medicines. They’re hosting a public meeting on July 14, 2025, and want your thoughts by August 14, 2025, to help shape the future—and keep the money flowing smoothly.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 0 costs, 2 mixed.
PDUFA Authority Expires September 2027
You should know the current law that lets FDA collect prescription drug user fees expires in September 2027. The FDA says that without new legislation after that date it will no longer be able to collect those fees that support human drug reviews; the Agency is holding a public meeting on July 14, 2025 and accepting comments through August 14, 2025 as part of the reauthorization process.
Possible Changes to PDUFA Fee Structures
FDA is requesting input on whether to change the current fee structures and amounts that fund the prescription drug user fee program. If fee structures or amounts are changed in future reauthorization negotiations, companies that submit marketing applications could see their fee obligations altered.
PDUFA VII Commitments Support New Therapies
Under the current PDUFA VII (in effect through FY 2027), FDA committed resources and new programs to support review of cell and gene therapies, include allergenic extract products, add timelines for pre-approval review of certain postmarketing items, create two new meeting types (Type D and INTERACT), and launch four pilot programs (Rare Diseases Endpoint Advancement Pilot; Advancing Real-World Evidence Program; Chemistry, Manufacturing, and Controls Development and Readiness Pilot; Split Real Time Application Review).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-08823, Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: HRSA Ryan White HIV/AIDS Program Part F National AIDS Education and Training Center Program Activities, OMB No. 0906-XXXX New
HRSA is planning to collect new information to help improve training for healthcare providers who treat people with HIV. They want your feedback on this plan by July 18, 2025, before officially moving forward. This effort aims to boost the skills of medical teams nationwide without adding extra costs right now.
Next: 2025-08825, Proposed Extension of Information Collection Request Submitted for Public Comment; Comment Request on Burden Related to Informing Participant of Group Health Plan or Health Insurance
The IRS wants to keep collecting info about how group health plans tell people they can pick a primary care doctor. This affects businesses and nonprofits that offer these plans, with no changes to the current rules or extra costs. If you have thoughts, send them by July 18, 2025, so your voice counts!